Summary:
Click image to enlarge
A Randomized, Double-Blinde, Placebo-Controlled and Delayed Start Study of LY3314814 in Mild Alzheimer's Disease Dementia (The Daybreak Study)
Qualified Participants Must:
• Be between 55 and 85 years of age
•
Have experienced a gradual loss of memory over the last 6 months
OR
•Have been diagnosed with mild Alzheimer's disease
Qualified Participants May Receive:
Compensation for time and travel is available.